Back to top
more

Cullinan Therapeutics, Inc. (CGEM)

(Delayed Data from NSDQ)

$19.91 USD

19.91
721,775

-0.40 (-1.97%)

Updated Jul 25, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?

Ocuphire (OCUP) is expected to provide updates on the clinical development of its lead retinal product candidate, APX3330, to treat diabetic retinopathy, in fourth-quarter 2023 earnings release.

Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?

On Puma Biotechnology's (PBYI) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.

Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?

Devoid of marketed drugs, investors will focus on Avalo Therapeutics' (AVTX) lead pipeline drug when it reports fourth-quarter earnings results.

Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?

Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings.

Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.

Moderna (MRNA) Gears Up for Q4 Earnings: Will It Top Estimates?

Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports fourth-quarter earnings.

Celularity (CELU) to Report Q4 Earnings: What's in the Cards?

Devoid of marketed drugs, investors will focus on updates on Celularity's (CELU) pipeline candidates when it reports its fourth-quarter earnings.

Company News for Jun 7, 2021

Companies in the news are: REGN, CHRS, SENS, CGEM

Cullinan (CGEM) Rises on Promising Phase I Cancer Study Data

Cullinan Oncology (CGEM) is developing its sole pipeline candidate, CLN-081, as a potential treatment for lung cancer in a phase I/IIa study.